⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
FBIO News
Fortress Biotech, Inc.
Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
FBIO
FBIOP
Form 8-K
sec.gov
FBIOP
FBIO
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
globenewswire.com
DERM
FBIO
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
globenewswire.com
FBIO
DERM
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP
Form 8-K
sec.gov
FBIOP
FBIO
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
globenewswire.com
FBIO
FBIOP
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
globenewswire.com
FBIO
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
globenewswire.com
FBIO